1. Introduction {#sec1}
===============

A method to identify the bioactive components in traditional Chinese medicine (TCM) from their complex mixtures is a critical challenge of TCM research. Because of its intuitive and efficient characteristics, molecular docking has become an important means for the identification of TCM bioactive components. The basis of identification via molecular docking involves one or multiple target proteins and the components being screened; ultimately, the components that specifically act on target protein can be identified, such as TCM bioactive components. In the screening process, a single target or multiple targets are chosen, usually targets associated with a specific disease. Methods for choosing targets are generally based on a database of disease-associated targets, a key target in a signaling transduction network or from the literature \[[@B1]--[@B3]\]. Because of the complexity of a disease, multiple targets may be associated with it. Therefore, the target proteins selected may not be the actual targets affected by TCM, or it may not be possible to screen against all of the associated targets. Therefore, the bioactive components obtained by molecular docking may not be the components that actually cured the corresponding disease or have been left out.

The development of chemical informatics and bioinformatics has led to the accumulation of data on TCM components, target proteins, and gene expression profiles. To determine a method for the selection of target proteins for molecular docking guided by the ideas of system pharmacology, this study proposed a method for determining the target proteins of TCM and then identified the bioactive components of TCM by molecular docking. This method has been designated the gene expression profile similarity-based identification (GEPSI) method. The basic concept is to choose the gene expression profiles that are targeted by small molecule drugs in Cmap based on the principle that they have higher comparability with the gene expression profiles of a TCM, and calculate the gene expression profiles similarity between the TCM and the small molecule drugs. The target proteins of the small molecule drugs that have higher similarity scores could be considered TCM targets. Aiming at these target proteins, virtual screening is carried out to screen the TCM components, ultimately identifying the bioactive components. Because it considers the entirety of the TCM components and all of the genes affected as the object, this method could embody the holistic thinking of TCM research more concretely. This method provides an effective means for the identification of TCM bioactive components and could serve as a basis for drug repositioning, quality control, and TCM drug design.

2. Methods and Materials {#sec2}
========================

2.1. Principle of GEPSI {#sec2.1}
-----------------------

Both TCMs and small molecule drugs all can affect gene expression. By comparing the gene expression profiles before and after treatment with TCM or a small molecule drug, up- and downregulated differentially expressed genes can be identified. Then, these up and downregulated differentially expressed genes that are affected by TCMs and small molecule drugs can be compared, and a similarity score can be obtained. If the similarity score is high, the TCM and the small molecule drug may have similar pharmacological action, and the target proteins for the small molecule drugs that have higher similarity score can be considered targets for the TCM. Using these proteins as the targets, we can finally identify the bioactive components of a TCM by molecular docking. We also discuss each step of the ITPI method ([Figure 1](#fig1){ref-type="fig"}) in detail in this paper.

### 2.1.1. Gene Expression Profile Data {#sec2.1.1}

The Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>) contains some gene expression profiles which were treated with components, herbs, and TCM formulae. These data were utilized to carry out TCM-related research. Connectivity Map (CMap, <https://www.broadinstitute.org/cmap/>) is a gene expression profile database related to small molecule drugs \[[@B4]\]. Cmap establishes the relations of small molecule drugs, genes, and diseases according to the gene expression differences in human tumor cell lines after treatment with small molecule drugs. By comparing the similarity of different gene expression profiles, Cmap is mainly applicable to the areas of drug development, such as drug repositioning. Different human tumor cell lines (HL60, MCF7, PC3, SKMEL5, and ssMCF7) were treated with small molecules drugs at different concentrations (10 nM, 100 nM, 1 *μ*M, and 10 *μ*M) for different times (6 h, 12 h). At present, Cmap contains data for 1309 small molecule drugs and more than 7000 gene expression profiles. Of these 1309 drugs, 556 drugs were recorded in DrugBank. Of these 556 drugs, 522 drugs had the data of target protein. This study chose gene expression profiles that had high similarity to TCMs with respect to the same cell lines types and platforms.

### 2.1.2. The Determination of Up and Downregulated Genes {#sec2.1.2}

The differentially expressed genes were determined using the bioinformatics toolbox of Matlab \[[@B5]\]. A*t*-test and false discovery rate (FDR) of multiple hypothesis testing were performed on each gene. Significant differentially expressed genes were detected by random sample replacement (*P* \< 0.05, FDR ≤ 0.1). Up and downregulated genes were distinguished by the magnitude of fold change (FC). If FC ≥ 2, then the significant differentially expressed genes were up-regulated genes, and if FC ≤ 0.5, then the significant differentially expressed genes were downregulated genes.

### 2.1.3. The Similarity Computation of the Gene Expression Profile {#sec2.1.3}

The up- and downregulated genes were used to calculate the gene expression profile similarity. Using up and downregulated genes as the base data, the gene expression profile similarity was automatically calculated in Cmap by the K-S algorithm \[[@B4], [@B6]\]. A similarity comparison yielded the similarity scores of the gene expression profiles of each small molecule drugs and TCM. Similarity scores fell between −1 and 1. If 0 ≤ similarity scores ≤ 1, the pharmacological action of a small molecule drug and TCM were similar, and a higher absolute value of the similarity score indicated a greater similarity; if −1 ≤ similarity scores ≤ 0, the pharmacological action of a small molecule drug and TCM were adverse, and a higher absolute value indicated less similarity.

### 2.1.4. Determination of the TCM Target Proteins {#sec2.1.4}

If the similarity score for the gene expression profiles of a small molecule drug and TCM was high, then their pharmacological action was similar. The target proteins of a small molecule drugs were considered TCM targets. This study only considered the top 10 small molecule drugs that had a definite pharmacological action and their target proteins were recorded in DrugBank version 4.3.

### 2.1.5. Data for the TCM Components {#sec2.1.5}

The components of a TCM formula were collected from TCMD \[[@B8]\] and TCMSP \[[@B9]\]. The components were supplemented and perfected by the literature in CNKI and PubMed (1979\~2017). The name, structure, and SMILES string of a component was recorded. For components with synonyms, the repetitive components were deleted by the "full structure" algorithm in "ChemBioFinder for Office 12.0".

### 2.1.6. Determination of Bioactive Components of a TCM {#sec2.1.6}

The three-dimensional structure was downloaded from the PDB (<https://www.rcsb.org/pdb/home/home.do>), and the structure that had active ligands and higher resolution was preferentially selected. The preprocessing of the target protein included the deletion of ligands, water, and redundant protein conformations; the completion of missing or incomplete residues; the addition of hydrogens; and the distribution of related charges. The amino acids in the target protein that interact with the ligand were selected and were defined as the active pocket. The structure of components was transformed into a three-dimensional structure, endowed with a CHARMM force field and protonated in accordance with the corresponding pH. Molecular docking was carried out by LibDock \[[@B10]\], and the parameter settings were as follows: the "Conformation Method" was "BEST," the "Docking Preferences" was "High Quality," and the other parameters were set to the default. With the "LibDock Score" as the reference, the components that had a score higher than the ligand and the ranked in the top 10 were considered the bioactive components. This information allowed us to identify the bioactive components of the TCM.

2.2. The Application of GEPSI on SWT {#sec2.2}
------------------------------------

Si-Wu-Tang (SWT) is a well-known TCM formula and is prepared from four medicinal herbs including*Rehmanniae Radix Praeparata* (*Rehmannia glutinosa* Libosch.),*Angelicae Sinensis Radix* (*Angelica sinensis* (Oliv.) Diels),*Paeoniae Radix Alba* (*Paeonia lactiflora* Pall.), and*Chuanxiong Rhizoma* (*Ligusticum chuanxiong* Hort.).*SWT* and its series of decoctions (i.e., the Xiang-Fu-Si-Wu decoction, and the Tao-Hong-Si-Wu decoction) have been widely used in clinical gynecology practice for blood stasis syndrome, such as primary dysmenorrheal, breast cancer, and other estrogen-related diseases \[[@B11]--[@B15]\]. For*SWT*, this study applied the TCM bioactive components identification method based on the similarity of the gene expression profiles. In GEO, the number of gene expression profiles that*SWT* (0.0256 mg/mL, 0.256 mg/mL, and 2.56 mg/mL) acted on, MCF-7, was GSE23610. GSE23610 was obtained on the GPL570 platform (HG-U133_Plus_2) \[[@B16]\]. A total of 3905 gene expression profiles were selected in Cmap for the same cell line (MCF-7) and platform (HG-U133_Plus_2). These gene expression profiles involved 1294 small molecule drugs. In addition, 98 components of*Rehmanniae Radix Praeparata*, 215 components of*Angelicae Sinensis Radix*, 85 components of*Paeoniae Radix Alba*, and 258 components of*Chuanxiong Rhizoma* were collected. The collected components can be seen in the Supplemental [Information 1](#supplementary-material-1){ref-type="supplementary-material"}.

3. Results and Discussions {#sec3}
==========================

3.1. Up- and Downregulated Genes {#sec3.1}
--------------------------------

At*SWT* concentrations of 0.0256 mg/mL and 0.256 mg/mL, the expression of each gene did not obviously change, but when the*SWT* concentration was 2.56 mg/mL, the expression of each gene obviously changed. Therefore, the gene expression profile that was elicited by*SWT*(2.56 mg/mL) was chosen for follow-up research.

A*t*-test and false discovery rate (FDR) multiple hypothesis test were applied to each gene. A large number of genes were found to have biological differences; 442 genes were up-regulated and 189 were downregulated (Supplemental [Information 2](#supplementary-material-1){ref-type="supplementary-material"}).

3.2. The Small Molecule Drugs with High Similarity Scores {#sec3.2}
---------------------------------------------------------

After the similarity was computed, the similarity scores of the gene expression profiles for 1294 small molecular drugs and*SWT* were obtained. The top ten small molecule drugs that had explicit pharmacological action and their target proteins contained in DrugBank were retained. The results are shown in [Table 1](#tab1){ref-type="table"}.

3.3. The Primary Pharmacological Actions of the Top Ten Small Molecule Drugs {#sec3.3}
----------------------------------------------------------------------------

The primary pharmacological actions of the top ten small molecule drugs in [Table 1](#tab1){ref-type="table"} were investigated in the literature. The results are shown in [Table 2](#tab2){ref-type="table"}.

[Table 2](#tab2){ref-type="table"} shows that the pharmacological actions of the ten small molecule drugs all involve disease caused by an unbalanced estrogen level. Except for phenoxybenzamine and equilin, the primary pharmacological action of the remaining eight small molecule drugs was closely related to the treatment of breast cancer. Most of the eight drugs have an estrogenic effect. For example, resveratrol and genistein are phytoestrogens; estradiol is a natural estrogen that is secreted by mature ovarian follicles; diethylstilbestrol is a kind of estrogen that is a common endocrine medication for breast cancer. We often think that the occurrence of breast cancer is related to an excessive or imbalanced level of estrogen in the female body \[[@B47]\], and the regulation of immunity is an important method for the treatment of cancer. To summarize,*SWT* may have an anti-breast cancer effect because it has a high similarity score with the top ten small molecule drugs.

3.4. The Target Proteins That Were Used in Molecular Docking {#sec3.4}
------------------------------------------------------------

Of the top ten small molecule drugs, only the target proteins of four drugs have a three-dimensional structure in the PDB with a high resolution and corresponding bioactive ligands. Therefore, the target proteins of these four drugs were used for molecular docking studies ([Table 3](#tab3){ref-type="table"}).

3.5. Bioactive Components of SWT {#sec3.5}
--------------------------------

After molecular docking, the components whose LibDock score were higher than that of the ligand were identified as bioactive components (the LibDock score of the ligand is shown in Supplemental [Information 3](#supplementary-material-1){ref-type="supplementary-material"}). This study identified 46 bioactive components, including 12 components in*Paeoniae Radix Alba*, 4 components in*Chuanxiong Rhizoma*, 6 components in*Angelicae Sinensis Radix,* and 24 components in*Rehmanniae Radix Praeparata* (the results are shown in [Table 4](#tab4){ref-type="table"}). The 46 bioactive components act on 9 target proteins.

3.6. Verification of the Reliability of GEPSI {#sec3.6}
---------------------------------------------

[Table 4](#tab4){ref-type="table"} shows that*SWT* has anti-breast cancer activity through 46 bioactive components and these components acted on 9 target proteins. Most of the bioactive components, such as catalpol, verbascoside, and paeoniflorin, acted on multiple targets. The types and numbers of targets that the bioactive components acted on were diverse. If we only use one or a few proteins as targets, the bioactive components retrieved may be not complete. For example, 19 bioactive components, such as catalpol, aucubin, and melittoside will be not be retrieved when ISGO is the target protein. Therefore, we should consider all the targets that TCM could affect when a comprehensive bioactive components screening is carried out.

The proteins in [Table 4](#tab4){ref-type="table"} were the targets of resveratrol, diethylstilbestrol, estradiol, and genistein. According to the literature, these four components were estrogen or had an estrogen-like effect, and resveratrol and genistein had potent anti-breast cancer activity. Hence, the 46 bioactive components of*SWT* may also have anti-breast cancer and estrogen-like effects. Studies showed that catalpol, a DNA polymerase inhibitor, inhibited the proliferation of six human solid tumor cell lines by acting during the G0-G1 period. The naturally occurring iridoid catalpol is a Taq DNA polymerase inhibitor. However, the formation of analogs bearing one to three silyl ether groups led to antiproliferative compounds against a panel of six human solid tumor cell lines, with GI50 values in the range 1.8--4.8 *μ*M. Cell cycle studies revealed an arrest of the G0/G1 phase that was consistent with DNA polymerase inhibition \[[@B48]\]. Orientin could suppress the proliferation of MCF-7 and present specific dose-response relationships \[[@B49], [@B50]\]. Paeoniflorin could suppress the proliferation and spread of breast cancer cells through the Notch-1 pathway \[[@B51]\]. The effect of trigalacturonic acid on the proliferation inhibition of Bcap-3 in breast cancer cells was better and it may have an anti-breast cancer potential \[[@B52]\]. To summarize, we found some bioactive components did have the same effect as small molecule drugs via a literature research which indicated the reliability of the bioactive components identification method based on the similarity of gene expression profiles.

4. Conclusion {#sec4}
=============

This method was more accurate with the protein that TCM actually acted on as the target, and the result was more comprehensive than a determination of the target protein according to disease-related target databases and signal transduction networks. For example, there are 74 breast cancer-related targets in the Therapeutic Target Database (TTD), including the estrogen receptor (ER), the vascular endothelial growth factor receptor 1 (VEGFR1), and the epidermal growth factor receptor (EGFR). However, no evidence was available to support the selection of these proteins as targets. This study identified the target protein that*SWT* actually acted on by a gene expression similarity comparison, identified all the bioactive components of*SWT* by molecular docking, and then verified the reliability of this method through a literature investigation. GEPSI could serve as a rapid and effective method for the identification of TCM bioactive components. Although some time is necessary to perfect related databases, such as components of TCM and the target protein structure of small drugs, we believe the data that used in GEPSI will be more complete, and the results will be more accurate with the development of chemical informatics and bioinformatics.

Meanwhile, this study has also revealed that*SWT* had anti-breast cancer efficacy. However, there have been no studies of these effects. The Tao-hong Si-wu Decoction, a derivative formula, was proved to influence the upper limb swelling after breast cancer surgery and the quality of a chemotherapy patient\'s life \[[@B53], [@B54]\]. Research has shown that*Paeoniae Radix Alba*,*Chuanxiong Rhizoma*,*Rehmanniae Radix Praeparata,*and*SWT* have plant estrogen-like effects, but the bioactive components have not been identified \[[@B55]\]. The above studies indirectly illustrate the rationality that*SWT* has an anti-breast cancer effect. That is to say, GEPSI also can be used for drug repositioning. Now that the bioactive components have been identified, we can control the quality of the individual herbs. We can also design an anti-breast cancer drug combination based on the bioactive components in*SWT*.
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###### 

Supplementary Materials 1: it includes 656 components of SWT. These components were used for molecular docking. Supplementary Materials 2: 442 upregulated genes and 189 downregulated genes. Supplementary Materials 3: the LibDock score of the ligand.

###### 

Click here for additional data file.

![The workflow of GEPSI.](ECAM2018-6935350.001){#fig1}

###### 

Top ten small molecule drugs that have higher similarity scores with the gene expression profile of *SWT*.

  Cmap name            Mean    Enrichment   *P* value   Percent nonnull   Group in DrugBank
  -------------------- ------- ------------ ----------- ----------------- ------------------------------
  Phenoxybenzamine     0.955   1.000        0.00000     100               Approved
  Diethylstilbestrol   0.703   0.983        0.00004     100               Approved
  Anisomycin           0.695   0.990        0.00012     100               Experimental
  Equilin              0.609   0.970        0.00004     100               Approved
  Digoxigenin          0.609   0.950        0.00012     100               Approved
  Resveratrol          0.413   0.855        0.00002     100               Experimental/investigational
  Estradiol            0.389   0.774        0.00000     94                Approved/investigational
  Prochlorperazine     0.376   0.674        0.00012     88                Approved
  Genistein            0.352   0.686        0.00000     81                Investigational
  Thioridazine         0.344   0.626        0.00004     72                Approved

###### 

The primary pharmacological action of the top ten small molecule drugs.

  Drug                 Primary pharmacological action                                                                     References
  -------------------- -------------------------------------------------------------------------------------------------- --------------------
  Phenoxybenzamine     Hypertension; mediated peripheral vasodilation; pheochromocytoma                                   \[[@B17]--[@B19]\]
  Diethylstilbestrol   Menopausal syndrome; postmenopausal osteoporosis; breast cancer                                    \[[@B20]--[@B22]\]
  Anisomycin           Immunosuppression                                                                                  \[[@B23], [@B24]\]
  Equilin              Postmenopausal osteoporosis                                                                        \[[@B25]\]
  Digoxigenin          Hypertension; valvular heart disease; cell proliferation inhibition, such as breast cancer, etc.   \[[@B26]--[@B29]\]
  Resveratrol          Anticancer; immunoregulation                                                                       \[[@B30]--[@B33]\]
  Estradiol            Metastatic breast cancer                                                                           \[[@B34]--[@B36]\]
  Prochlorperazine     Antinausea after chemotherapy                                                                      \[[@B37], [@B38]\]
  Genistein            Anticancer; radiation protection; immunoregulation                                                 \[[@B39]--[@B42]\]
  Thioridazine         Anticancer; antischizophrenia                                                                      \[[@B43]--[@B46]\]

###### 

The target proteins of small molecule drugs that were used for molecular docking studies.

  Drug                 Mode of action   The Uniprot number   Abbreviation of protein   The PDB number
  -------------------- ---------------- -------------------- ------------------------- ----------------
  Diethylstilbestrol   Agonist          Q92731               ESR2                      1QKM
  Agonist              P03372           ESR1                 1X7R                      
  Unknown              O75469           NR1I2                4X1F                      
                                                                                       
  Resveratrol          Unknown          P03372               ESR1                      1QKT
  Unknown              Q92731           ESR2                 4J24                      
                                                                                       
  Estradiol            Agonist          P16083               NQO2                      1SG0
  Agonist              P68400           CSNK2A1              4RLL                      
                                                                                       
  Genistein            Unknown          P03372               ESR1                      3ERD
  Unknown              P62508           ESRRG                2GPP                      

###### 

The 46 bioactive components of *SWT*.

  ----------------------------------------------------------------------------------------------
  Herb                          Compound             PubChem\   LibDock score   Target protein
                                                     CID                        
  ----------------------------- -------------------- ---------- --------------- ----------------
  Shudi                         Catalpol             91520      130.006         1QKM

  Catalpol                      91520                127.034    1X7R            

  Catalpol                      91520                119.571    3ERD            

  Catalpol                      91520                120.630    4J24            

  Isoacteoside                  6476333              176.387    4RLL            

  Isoacteoside                  6476333              136.387    ISGO            

  Leucosceptoside A             10394343             134.596    ISGO            

  aucubin                       91458                119.278    3ERD            

  Cistanoside F                 44429870             143.468    1QKT            

  Cistanoside F                 44429870             127.692    ISGO            

  Melittoside                   11968737             151.290    4X1F            

  Acteoside                     5281800              178.203    4RLL            

  Acteoside                     5281800              150.245    ISGO            

  Martynoside                   44429856             148.239    ISGO            

  Forsythoside A                45358127             178.534    4RLL            

  Forsythoside A                45358127             146.041    ISGO            

  Ajugoside                     179611               119.032    4J24            

  Jioglutoside B                11968648             140.384    4X1F            

  Jioglutoside B                11968648             123.671    ISGO            

  Jioglutoside A                11968647             116.065    3ERD            

  Jionoside D                   9895632              130.081    ISGO            

  Echinacoside                  5281771              134.559    ISGO            

  Dihydrocatalpol               5705531              128.987    1QKM            

  Glutinoside                   24884124             131.718    1X7R            

  Glutinoside                   24884124             122.022    3ERD            

  Rehmannioside C               6325883              149.106    1QKT            

  Rehmannioside C               6325883              137.092    4J24            

  Rehmannioside C               6325883              153.335    4X1F            

  Rehmannioside C               6325883              135.653    ISGO            

  Rehmannioside B               6325882              145.167    1QKT            

  Rehmannioside B               6325882              143.713    4X1F            

  Rehmannioside B               6325882              126.837    ISGO            

  Rehmannioside A               86287413             142.582    1QKT            

  Rehmannioside A               86287413             138.007    4X1F            

  Rehmannioside A               86287413             138.555    ISGO            

  Daucosterol                   5742590              138.157    4X1F            

  Daucosterol                   5742590              135.135    ISGO            

  Geniposide                    107848               129.014    1X7R            

  Forsythiaside                 5281773              177.534    4RLL            

  Forsythiaside                 5281773              148.451    ISGO            

  8-Epiloganic acid             158144               128.867    1X7R            

  8-Epiloganic acid             158144               121.873    3ERD            

  sec-Hydroxyaeginetic acid     15693867             129.657    1QKM            

  sec-Hydroxyaeginetic acid     15693867             139.930    1QKT            

  sec-Hydroxyaeginetic acid     15693867             119.597    3ERD            

  sec-Hydroxyaeginetic acid     15693867             119.688    4J24            

  sec-Hydroxyaeginetic acid     15693867             177.998    4RLL            

  sec-Hydroxyaeginetic acid     15693867             149.140    4X1F            

  sec-Hydroxyaeginetic acid     15693867             149.648    ISGO            

                                                                                

  Danggui                       Orientin             5281675    126.131         4J24

  Orientin                      5281675              128.047    ISGO            

  Trigalacturonic acid          3641243              141.911    4X1F            

  Sphingomyelin                 52931203             121.153    3ERD            

  Daucosterol                   5742590              138.157    4X1F            

  Daucosterol                   5742590              135.135    ISGO            

  Senkyunolide                  91731751             170.306    4RLL            

  1,1,5-Trimethyl-2-formyl-\    None                 140.619    1QKT            
  cyclohea-2,5-diene-4-one                                                      

  1,1,5-Trimethyl-2-formyl-\    None                 142.328    2GPP            
  cyclohexa-2,5-diene-4-one                                                     

  1,1,5-Trimethyl-2-formyl-\    None                 123.128    4J24            
  cyclohexa-2,5-diene-4-one                                                     

  1,1,5-Trimethyl-2-formyl-\    None                 126.443    ISGO            
  cyclohexa-2,5-diene-4-one                                                     

  1,1,5-Trimethyl-2-formyl-\    None                 125.665    ISGO            
  cyclohexa-2,5-diene-4-one                                                     

                                                                                

  Chuanxiong                    Heptadecanoic acid   10429233   127.735         1X7R

  Heptadecanoic acid            10429233             124.190    4J24            

  Butyraldehyde                 14900                122.060    3ERD            

  Daucosterol                   5742590              138.157    4X1F            

  Daucosterol                   5742590              135.135    ISGO            

  Methyl 3,4-dimethylbenzoate   7852                 140.619    1QKT            

  Methyl 3,4-dimethylbenzoate   7852                 123.128    4J24            

  Methyl 3,4-dimethylbenzoate   7852                 125.665    ISGO            

                                                                                

  Baishao                       Paeonianin E         44256843   141.990         ISGO

  Peonin                        44253993             135.516    4X1F            

  Peonin                        44253993             124.317    ISGO            

  Stigmasterol Glucoside        6440962              134.691    ISGO            

  Paeonoside                    52952637             172.449    4RLL            

  Paeonoside                    52952637             133.551    ISGO            

  Paeoniflorin                  442534               149.657    1QKT            

  Paeoniflorin                  442534               126.988    1X7R            

  Paeoniflorin                  442534               122.872    4J24            

  Paeoniflorin                  442534               138.060    4X1F            

  Oxypaeoniflorin               429559               146.127    1QKT            

  Oxypaeoniflorin               429559               141.528    4X1F            

  Methyl linolelaidate          5362793              116.328    3ERD            

  Galloylpaeoniflorin           46882879             137.131    ISGO            

  Dotriacontane                 11008                127.379    ISGO            

  Acetytastragaloside           5282102              129.735    ISGO            

  Albiflorin                    162355               143.965    1QKT            

  1,2,3,6-Tetragalloylglucose   73178                137.874    ISGO            
  ----------------------------------------------------------------------------------------------
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